Adenocarcinoma, Pancreatic Cancer
Conditions
Brief summary
This is a phase 2 study (the second phase in testing a new drug or combination to see how effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib. The purpose of the study is to evaluate the antitumor activity of GSK2256098 and Trametinib in patients with advanced pancreatic cancer.
Detailed description
Trametinib is a drug that works by binding to and blocking certain proteins called mitogen-activated protein kinase kinase (MEK) 1 and MEK2 from working. MEK1 and MEK2 are important proteins that contribute to the growth of cancer cells. GSK2256098 is a drug that blocks a protein called focal adhesion kinase-1 (FAK) which is an important protein that contribute to the growth of cancer cells.
Interventions
DRUGGSK2256098
Small molecule inhibitor of focal adhesion kinase (FAK)
DRUGTrametinib
Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
Sponsors
GlaxoSmithKline
University Health Network, Toronto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, 18 years or older, able to give written consent * Pancreatic adenocarcinoma that is not responsive to standard therapies or for which there is no approved or curative therapy or for patients who refuse standard therapy * Have clinical, radiographic, or serologic progression after one prior line of chemotherapy for advanced disease. Patients who have received two or more prior lines of chemotherapy for advanced disease are not eligible. * Performance Status score of 0 or 1 * Measureable disease by RECIST version 1.1 * Able to swallow and retain oral medication * Have malignant disease that is amenable to biopsy and agree to collection of mandatory tumor biopsy samples. * Agrees to use contraception * Not pregnant * Adequate organ system function
Exclusion criteria
* Chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapy including investigational drugs within 28 days or 5 half lives. No prior MEK inhibitor, RAF inhibitors or a FAK inhibitors * Current use of a prohibited medication * Unresolved toxicity greater than Grade 1 from previous anticancer therapy unless the ongoing toxicity will not introduce additional risk factors and will not interfere with the study procedures. * Presence of active GI disease or other condition that could affect gastrointestinal absorption or predisposed to GI ulceration * Evidence of mucosal or internal bleeding * Anticoagulation with warfarin * Major surgery within the last four weeks * Malignancies related to HIV or HBV/HCV * Known active infection requiring parenteral or oral anti-infective treatment * Leptomeningeal disease. * Brain metastases * QTcF interval ≥ 480 msecs * History or evidence of current clinically significant uncontrolled arrhythmias * History of acute coronary syndromes, myocardial infarction, coronary angioplasty, or stenting or bypass grafting within six months of screening. * Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system. * Other clinically significant ECG abnormalities * Intra-cardiac defibrillators. * Presence of cardiac metastases. * Serious or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety or providing informed consent. * Known immediate or delayed hypersensitivity to any of the components of the study treatment(s). * Evidence of severe or uncontrolled systemic diseases * Pregnant or lactating * History of retinal vein occlusion * History of interstitial lung disease or pneumonitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients who experience complete response, partial response, or stable disease | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events based on frequency and proportion of total patients, by system organ class and preferred term. | 2 years |
| Percentage of patients achieving either a complete or partial tumor response. | 2 years |
| Interval between the date of randomization and the earliest date of disease progression or death due to any cause | 2 years |
| Interval between the first date of CR or PR and the earliest date of disease progression or death due to any cause. | 2 years |
Countries
Canada
Outcome results
None listed